Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant
Bayer AG (ETR: BAYN) announced the completion of its acquisition of Perfuse Therapeutics, Inc., securing...
ETR: BAYN
Bayer AG Inaugurates Second Consumer Health Innovation Center in China, Expanding Skin and Digestive Health Partnerships
Bayer AG (ETR: BAYN) announced the inauguration of its second Bayer Consumer Health China Center...
Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose
Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...
Bayer Announces Consumer Health Leadership Restructuring with New Global and U.S. Appointments
Bayer AG (ETR: BAYN) announced today a strategic leadership restructuring within its Consumer Health division,...
Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at...
Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version...
Bayer’s Kerendia Receives FDA Priority Review for Expanded Indication in Type 1 Diabetes-Associated Chronic Kidney Disease
Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted...
Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial
Bayer AG (ETR: BAYN) announced today that the U.S. Food and Drug Administration (FDA) has...
Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...
Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive...
Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff
Bayer AG (ETR: BAYN) released its 2025 financial results, recording EUR 45.6 billion (USD 52.84 billion) in group...
Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer
Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...
Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery
Bayer AG (ETR: BAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five‑year collaboration to...
Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation
Bayer AG (ETR: BAYN) announced an agreement with Attralus, Inc. to acquire two investigational molecular imaging...
Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC
Bayer AG (VIE: BAYN) announced that cevatertinib (BAY 2927088) has been granted Breakthrough Therapy Designation (BTD)...
Bayer’s HYRNUO Wins FDA Approval for HER2-Mutated Lung Cancer
Bayer AG (ETR: BAYN) announced that sevabertinib (trade name HYRNUO) received U.S. FDA approval for...
Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth
Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year...
Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval...
Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)...
Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor
German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August...